Tumor immunoediting and immunosculpting pathways to cancer progression.
about
Cancer-Associated Myeloid Regulatory CellsEffects of opioids on immunologic parameters that are relevant to anti-tumour immune potential in patients with cancer: a systematic literature reviewHMGB1 mediates endogenous TLR2 activation and brain tumor regressionLesion human leukocyte antigen-F expression is associated with a poor prognosis in patients with hepatocellular carcinomaMacrophage-tumor cell interactions regulate the function of nitric oxideImmunosignature system for diagnosis of cancer.Time-Frequency Analysis of Peptide Microarray Data: Application to Brain Cancer Immunosignatures.Ultrastructural observations on inflammatory angiogenesis in gastric carcinomas with massive neutrophil infiltration.Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells.Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinomaCancer immunoediting from immunosurveillance to tumor escape in microvillus-formed niche: a study of syngeneic orthotopic rat bladder cancer model in comparison with human bladder cancer.Endometriosis and ovarian cancer: a review of clinical, pathologic, and molecular aspects.CD4+CD25hiCD127low regulatory T cells are increased in oral squamous cell carcinoma patients.PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice.Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophilsPathway-based evaluation in early onset colorectal cancer suggests focal adhesion and immunosuppression along with epithelial-mesenchymal transition.CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivationChemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactionsIntratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens.Theiler's murine encephalomyelitis virus as a vaccine candidate for immunotherapy.Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.Neutrophils recruit and activate human endothelial colony-forming cells at the site of vessel injury via P-selectin glycoprotein ligand-1 and L-selectin.Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic miceEpithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases.Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.Nuclear-enriched abundant transcript 1 as a diagnostic and prognostic biomarker in colorectal cancer.Infiltrating neutrophils promote renal cell carcinoma progression via VEGFa/HIF2α and estrogen receptor β signals.Macrophages define the invasive microenvironment in breast cancer.Immune surveillance: a balance between protumor and antitumor immunity.An evolutionary explanation for the perturbation of the dynamics of metastatic tumors induced by surgery and acute inflammation.Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis.Immunomics in Skin Cancer - Improvement in Diagnosis, Prognosis and Therapy Monitoring.Aberrant human leucocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma.Current concepts on the role of inflammation in COPD and lung cancer.Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR familyPotential role of immunotherapy in advanced non-small-cell lung cancerImmune escape mechanisms of intraocular tumors.Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis.Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.A prognostic model combining CD4/CD8 ratio and N stage predicts the risk of distant metastasis for patients with nasopharyngeal carcinoma treated by intensity modulated radiotherapy.
P2860
Q26750382-E17F4FC0-4200-4B3A-B516-30C215991F07Q26860175-EC1FEF43-0983-4144-A539-EB203E37A73FQ27307459-FD615505-16A0-48A0-9CA2-D70B6F34F02AQ28252431-881FEAD0-3AC0-4ABC-AB95-78844217136CQ28384490-B9A10F5E-6E1F-4879-B3C5-F82C22E71BF9Q30585860-6A80B42A-22B3-492B-8421-9E2285B3A533Q30979384-19761CA7-1C50-40EE-B6C2-4912B7B9CE66Q33405298-8FCB9CDE-DC16-43E6-9DCC-282005EFFBF7Q33795345-05C15F1D-D1EC-4311-B0EF-A9A5FF08F0DEQ33865610-4CE9B5B0-3D28-4ADF-9E9E-D3CF00F62C14Q33920324-6FE32E1E-70D1-401A-A506-4D14AB964784Q34033619-89EFCA10-57F1-40F9-A30F-A3567406F142Q34083746-CFCE6BE9-BF1A-4BCF-9CCF-FE1874A46A34Q34093865-7BCB485A-34C8-4156-8E2D-6CAD12680B1FQ34163579-785DAFC6-7C37-433E-A19E-3D28D17836A7Q34229772-6F2DD4FE-0C79-4422-B3A3-2B714151101DQ34346803-51D6FFD4-1EB9-4ED3-8EE8-BBC5AB546A6BQ34477550-C497A612-DF10-4174-B59D-DB0B4763A11EQ34757171-082CDC2F-FA30-4D28-BF2F-088A48FA9E37Q34995286-F3211920-A0EB-47C1-9266-C57D9452E30AQ35000651-D41B29E6-05D6-427A-9B1E-8C4B863C0DF5Q35113822-4CD76185-FD17-4C6A-8C5E-E89D8A53A744Q35740182-11EF7DBB-735F-4C10-8243-6BDC27A28FA6Q35762816-CCDAA7CC-D59C-47E3-8049-68F8EDF8822AQ36004284-FFBD180E-1132-4A58-A7D0-F207364D7A0EQ36267118-AEED2847-B2CD-4A12-B4C1-FC28A12ED1E8Q36326380-43C241AB-76B7-4CC1-BB1A-0386AF34648FQ36838542-F49A392B-39C4-4B02-B278-39DD99316BEFQ37097545-CE1D3BC9-0407-4C94-82FF-CD4DE2E5FA04Q37129834-7F2F2176-C7DB-4978-AB87-ADC82AD424FEQ37234841-3158C219-A89E-465C-9CF1-8D2AAFC41151Q37290632-E2EC3A09-60D7-4D74-B133-EF0DCD4E6501Q37294991-10BCFF63-49A8-4FC5-A94B-1DA3CB6311DEQ37316084-29A3B1EA-DD21-4E2E-AEA8-5EC83CCA577EQ37316604-11E53A12-F3E5-4F7F-90D8-3EFFBC0AE8A3Q37527869-DFC65F70-E1D4-44F3-A7A0-54DD3D719C55Q37535138-E7CA4879-37A2-4D46-A4BD-31EE439EF5BBQ37536862-67891193-2FA0-4597-8C48-D947239ABDA5Q37542216-B729E5C8-09FB-45EA-A852-DE6A433EC208Q37564833-1AF7F3F0-D382-4B11-8C08-E9B657654C83
P2860
Tumor immunoediting and immunosculpting pathways to cancer progression.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Tumor immunoediting and immunosculpting pathways to cancer progression.
@en
type
label
Tumor immunoediting and immunosculpting pathways to cancer progression.
@en
prefLabel
Tumor immunoediting and immunosculpting pathways to cancer progression.
@en
P2093
P2860
P1476
Tumor immunoediting and immunosculpting pathways to cancer progression
@en
P2093
Keith L Knutson
Maciej Kmieciak
Masoud H Manjili
P2860
P304
P356
10.1016/J.SEMCANCER.2007.06.009
P577
2007-06-26T00:00:00Z